A drug has been developed that prevents metastasis of prostate cancer
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Scientists from the United States have developed a drug that prevents the spread of metastases in prostate cancer. According to EurekAlert !, an employee of Northwestern University in Chicago, Li Xu (Li Xu) spoke about the development at the annual conference of the American Association for Research on Cancer (AACR).
The research team conducted a series of experiments on laboratory mice. They transplanted the animals with malignant cells taken from patients with prostate cancer. For five weeks rodent was given an experimental preparation KBU2046.
Mice from the control group had cancer metastases in the lungs, which indicates the proliferation of malignant cells, whereas in the gryunons receiving KBU2046, metastases could not be detected. In addition, the results of experiments on cultures of human malignant cells showed no toxicity in the experimental drug.
According to researchers, in malignant cells there are proteins that trigger their aggressive spread. KBU2046 binds to such proteins and deactivates them. Scientists expressed the hope that the results of the study will be confirmed during clinical trials of the drug.
[